JPWO2021183934A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021183934A5 JPWO2021183934A5 JP2022554833A JP2022554833A JPWO2021183934A5 JP WO2021183934 A5 JPWO2021183934 A5 JP WO2021183934A5 JP 2022554833 A JP2022554833 A JP 2022554833A JP 2022554833 A JP2022554833 A JP 2022554833A JP WO2021183934 A5 JPWO2021183934 A5 JP WO2021183934A5
- Authority
- JP
- Japan
- Prior art keywords
- bcma
- subject
- cell maturation
- dihydrobromide
- maturation antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025139609A JP2025168430A (ja) | 2020-03-13 | 2025-08-25 | ニロガセスタットとｂｃｍａ指向療法での併用療法およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062989372P | 2020-03-13 | 2020-03-13 | |
| US62/989,372 | 2020-03-13 | ||
| PCT/US2021/022177 WO2021183934A1 (en) | 2020-03-13 | 2021-03-12 | A combination therapy with nirogacestat and a bcma-directed therapy and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025139609A Division JP2025168430A (ja) | 2020-03-13 | 2025-08-25 | ニロガセスタットとｂｃｍａ指向療法での併用療法およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023517243A JP2023517243A (ja) | 2023-04-24 |
| JPWO2021183934A5 true JPWO2021183934A5 (enExample) | 2024-03-21 |
| JP7781764B2 JP7781764B2 (ja) | 2025-12-08 |
Family
ID=75396879
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554833A Active JP7781764B2 (ja) | 2020-03-13 | 2021-03-12 | ニロガセスタットとｂｃｍａ指向療法での併用療法およびその使用 |
| JP2025139609A Pending JP2025168430A (ja) | 2020-03-13 | 2025-08-25 | ニロガセスタットとｂｃｍａ指向療法での併用療法およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025139609A Pending JP2025168430A (ja) | 2020-03-13 | 2025-08-25 | ニロガセスタットとｂｃｍａ指向療法での併用療法およびその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230121547A1 (enExample) |
| EP (1) | EP4132515A1 (enExample) |
| JP (2) | JP7781764B2 (enExample) |
| KR (1) | KR20230009873A (enExample) |
| CN (1) | CN115916188A (enExample) |
| AR (1) | AR121566A1 (enExample) |
| AU (1) | AU2021236340A1 (enExample) |
| BR (1) | BR112022018251A2 (enExample) |
| CA (1) | CA3171267A1 (enExample) |
| CL (1) | CL2022002479A1 (enExample) |
| CO (1) | CO2022014388A2 (enExample) |
| IL (1) | IL296075A (enExample) |
| MX (1) | MX2022011258A (enExample) |
| PE (1) | PE20230614A1 (enExample) |
| TW (1) | TW202200132A (enExample) |
| WO (1) | WO2021183934A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023034917A1 (en) | 2021-09-01 | 2023-03-09 | Springworks Therapeutics, Inc. | Synthesis of nirogacestat |
| WO2023064872A1 (en) * | 2021-10-14 | 2023-04-20 | Precision Biosciences, Inc. | Combinations of anti-bcma car t cells and gamma secretase inhibitors |
| CN118338900A (zh) * | 2021-11-05 | 2024-07-12 | 斯普林渥克斯治疗有限公司 | 含尼罗加司他的组合物和治疗 |
| US20240408067A1 (en) * | 2021-11-23 | 2024-12-12 | Teva Pharmaceuticals International Gmbh | Solid state forms of nirogacestat salts |
| US12138246B2 (en) | 2022-05-20 | 2024-11-12 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| US12036207B2 (en) | 2022-05-20 | 2024-07-16 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| US11951096B2 (en) | 2022-05-20 | 2024-04-09 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| PE20250395A1 (es) | 2022-05-20 | 2025-02-11 | Springworks Therapeutics Inc | Tratamientos con nirogacestat |
| AU2024231546A1 (en) * | 2023-03-09 | 2025-10-02 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of nirogacestat dihydrobromide, and preparation method therefor and use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10149855B2 (en) * | 2014-02-05 | 2018-12-11 | The Trustees Of Columbia University In The City Of New York | Gamma-secretase inhibition reduce APOC3 levels and plasma triglycerides |
| MX2018000999A (es) * | 2015-07-24 | 2018-11-09 | Oncotracker Inc | Moduladores de gamma secretasa para el tratamiento de disfuncion del sistema inmunologico. |
| MX2019009552A (es) * | 2017-02-17 | 2019-10-02 | Hutchinson Fred Cancer Res | Terapias de combinacion para el tratamiento de canceres relacionados con el antigeno de maduracion de celulas b (bcma) y trastornos autoinmunitarios. |
| US20200055948A1 (en) * | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| EP3615068A1 (en) * | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| EP3611970B1 (en) | 2017-05-05 | 2023-08-02 | Huawei Technologies Co., Ltd. | Location assistance data transmission |
| CA3080395A1 (en) * | 2017-11-06 | 2019-05-09 | Juno Therapeutics, Inc. | Combination of a cell therapy and a gamma secretase inhibitor |
| WO2019094626A1 (en) * | 2017-11-08 | 2019-05-16 | Fred Hutchinson Cancer Research Center | Bispecific antibody compositions and related methods for improved pretargeted radioimunotherapies |
| WO2019143818A1 (en) * | 2018-01-17 | 2019-07-25 | Mingsight Pharmaceuticals, Inc. | Combination therapy for the treatment of cancer |
| AU2019275284A1 (en) * | 2018-05-24 | 2021-01-14 | Ayala Pharmaceuticals Inc. | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and immunotherapeutics and methods of use thereof |
| CN118459594A (zh) * | 2018-06-01 | 2024-08-09 | 诺华股份有限公司 | 针对bcma的结合分子及其用途 |
| MX2021012407A (es) * | 2019-04-10 | 2021-11-12 | Glaxosmithkline Ip Dev Ltd | Terapia de combinacion con un anticuerpo anti bcma y un inhibidor de gamma secretasa. |
| KR102772889B1 (ko) * | 2019-08-09 | 2025-02-26 | 화이자 인코포레이티드 | (s)-2-(((s)-6,8-디플루오로-1,2,3,4-테트라하이드로나프탈렌-2-일)아미노)-n-(1-(2-메틸-1-(네오펜틸아미노)프로판-2-일)-1h-이미다졸-4-일)펜탄아미드의 고체 상태 형태 및 이의 용도 |
-
2021
- 2021-03-12 TW TW110108930A patent/TW202200132A/zh unknown
- 2021-03-12 CA CA3171267A patent/CA3171267A1/en active Pending
- 2021-03-12 EP EP21716907.7A patent/EP4132515A1/en active Pending
- 2021-03-12 US US17/906,089 patent/US20230121547A1/en active Pending
- 2021-03-12 IL IL296075A patent/IL296075A/en unknown
- 2021-03-12 MX MX2022011258A patent/MX2022011258A/es unknown
- 2021-03-12 BR BR112022018251A patent/BR112022018251A2/pt unknown
- 2021-03-12 JP JP2022554833A patent/JP7781764B2/ja active Active
- 2021-03-12 PE PE2022001961A patent/PE20230614A1/es unknown
- 2021-03-12 CN CN202180034598.4A patent/CN115916188A/zh active Pending
- 2021-03-12 WO PCT/US2021/022177 patent/WO2021183934A1/en not_active Ceased
- 2021-03-12 KR KR1020227034017A patent/KR20230009873A/ko active Pending
- 2021-03-12 AR ARP210100641A patent/AR121566A1/es unknown
- 2021-03-12 AU AU2021236340A patent/AU2021236340A1/en active Pending
-
2022
- 2022-09-12 CL CL2022002479A patent/CL2022002479A1/es unknown
- 2022-10-10 CO CONC2022/0014388A patent/CO2022014388A2/es unknown
-
2025
- 2025-08-25 JP JP2025139609A patent/JP2025168430A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220088196A1 (en) | Means and Methods for Treating Tumorous Diseases | |
| DK2055313T3 (en) | Treatment of Hematologic Malignancies Related to Circulating Tumor Cells Using Chimeric Anti-CD20 Antibody | |
| EP3800203A1 (en) | Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2 | |
| Sacchi et al. | Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab | |
| KR20230008197A (ko) | 암을 치료하기 위한 방법, 요법 및 용도 | |
| EA004107B1 (ru) | Комбинированная терапия в-клеточных лимфом, предусматривающая введение антитела против cd20 | |
| JP2007512243A5 (enExample) | ||
| Frey et al. | The promise of chimeric antigen receptor T-cell therapy | |
| TW202224703A (zh) | 治療癌症之方法、治療劑及用途 | |
| Robak et al. | Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia | |
| JPWO2021183934A5 (enExample) | ||
| KR20200010472A (ko) | 항-cd19 항체 및 베네토클락스 조합 치료에 대한 치료 패러다임 | |
| Russler-Germain et al. | T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and future directions | |
| CA3087346A1 (en) | Combination immunotherapy and chemotherapy for the treatment of a hematological malignancy | |
| Jäeger et al. | Rituximab (anti‐CD20 monoclonal antibody) as consolidation of first‐line CHOP chemotherapy in patients with follicular lymphoma: a phase II study | |
| Tan et al. | Targeting BCMA in multiple myeloma | |
| Banerjee et al. | Emerging new cell therapies/immune therapies in B-cell non-Hodgkin's lymphoma | |
| Wang et al. | Bispecific Antibodies for Multiple Myeloma: Recent Advancements and Strategies for Increasing Their Efficacy | |
| CN101331151A (zh) | 治疗肿瘤性疾病的方式和方法 | |
| Longo | Biologic agents and approaches in the management of patients with lymphoma: a critical appraisal | |
| JPWO2020222668A5 (enExample) | ||
| Rai et al. | Monoclonal antibodies in chronic lymphocytic leukemia | |
| Ayyappan et al. | SOHO State of the Art Updates and Next Questions| Manuscript Title: Bispecific T-Cell Engagers: Sequencing, B-Cell Maturation Antigen, GPRC5D, and Resistance | |
| AU2013202375B2 (en) | Means and Methods for the Treatment of Tumorous Diseases | |
| Batlevi et al. | Chimeric Antigen Receptor T Cells for Lymphomas: Methods, Data, and Challenges |